The efficacy and tolerability of MK-0633, a 5-lipoxygenase inhibitor, in chronic asthma

scientific article published on 25 September 2011

The efficacy and tolerability of MK-0633, a 5-lipoxygenase inhibitor, in chronic asthma is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.RMED.2011.08.019
P698PubMed publication ID21945511

P2093author name stringWilliam D Hanley
Steven S Smugar
Theodore F Reiss
Barbara A Knorr
Yasmine S Wasfi
César Villarán
Celine Le Bailly de Tilleghem
P433issue1
P921main subjectasthmaQ35869
P304page(s)34-46
P577publication date2011-09-25
P1433published inRespiratory MedicineQ2659932
P1476titleThe efficacy and tolerability of MK-0633, a 5-lipoxygenase inhibitor, in chronic asthma
P478volume106

Reverse relations

cites work (P2860)
Q89411784Application of Docking Analysis in the Prediction and Biological Evaluation of the Lipoxygenase Inhibitory Action of Thiazolyl Derivatives of Mycophenolic Acid
Q37066194Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study
Q38925866Elucidation of the molecular mechanism and the efficacy in vivo of a novel 1,4-benzoquinone that inhibits 5-lipoxygenase.
Q35886279Phenotyping drug polypharmacology via eicosanoid profiling of blood.
Q59830619Targeting Metalloenzymes for Therapeutic Intervention

Search more.